![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Corgentech Treats First Patient in Phase I/II Trial of Eczema Drug Candidate
Corgentech Treats First Patient in Phase I/II Trial of Eczema Drug Candidate
May 25, 2005
Corgentech has begun treating patients in a multicenter Phase I/II clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema that affects about 15 million adults in the U.S.
This is the first of two Phase I/II trials to be initiated. The second trial will be conducted in Australia and Switzerland in approximately 120 patients and is expected to initiate enrollment by mid-2005.
The multicenter, randomized, double-blind, dose-ranging trial will evaluate the safety and feasibility of repeated application of three concentrations of NF-kB Decoy to the skin of adult patients with mild-to-moderate eczema. NF-kB Decoy is a highly selective and potent inhibitor of the transcription factor, NF-kB, which is implicated in inflammatory diseases such as eczema, asthma and inflammatory bowel disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct